Literature DB >> 16890194

Breast carcinoma specific antibody selection combining phage display and immunomagnetic cell sorting.

Christine Mazuet1, Dimitri Lerouge, Marie-Alix Poul, Nathalie Blin.   

Abstract

To discover new specific antibodies directed against disseminated carcinoma cells in breast cancer patients, a strategy combining single-chain variable fragment (scFv) phage display and immunomagnetic cell sorting was developed. A selection model, in which ErbB2-expressing breast carcinoma SKBR3 cells are spiked into a 50-fold excess of lymphocytes, was setup. Selection conditions, optimized using the previously characterized ErbB2-specific F5 phage scFv, led to an outstanding phage enrichment yield of 25,000 after only one round. This protocol applied to human nai ve and synthetic phage display antibody libraries led to the selection, in only two rounds, of individual scFv clones (43 out of 46 tested) specific for non-epithelial carcinoma antigens expressed on SKBR3 cells. This strategy is fully applicable to metastatic cells in effusions from breast carcinoma patients and shall lead to the discovery of immunotools crucial for novel diagnostic and therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890194     DOI: 10.1016/j.bbrc.2006.07.087

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display.

Authors:  Klervi Even-Desrumeaux; Damien Nevoltris; Marie Noelle Lavaut; Karima Alim; Jean-Paul Borg; Stéphane Audebert; Brigitte Kerfelec; Daniel Baty; Patrick Chames
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

Review 2.  Selection strategies for anticancer antibody discovery: searching off the beaten path.

Authors:  David Sánchez-Martín; Morten Dræby Sørensen; Simon Lykkemark; Laura Sanz; Peter Kristensen; Erkki Ruoslahti; Luis Álvarez-Vallina
Journal:  Trends Biotechnol       Date:  2015-03-26       Impact factor: 19.536

Review 3.  Ligandomics: a paradigm shift in biological drug discovery.

Authors:  Wei Li; Iok-Hou Pang; Mario Thiego F Pacheco; Hong Tian
Journal:  Drug Discov Today       Date:  2018-01-08       Impact factor: 7.851

4.  Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

Authors:  Anne-Laure Goenaga; Yu Zhou; Christine Legay; Houcine Bougherara; Lan Huang; Bin Liu; Daryl C Drummond; Dmitri B Kirpotin; Christian Auclair; James D Marks; Marie-Alix Poul
Journal:  Mol Immunol       Date:  2007-05-10       Impact factor: 4.407

5.  State of the art in tumor antigen and biomarker discovery.

Authors:  Klervi Even-Desrumeaux; Daniel Baty; Patrick Chames
Journal:  Cancers (Basel)       Date:  2011-06-09       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.